1. Home
  2. LITM vs IFRX Comparison

LITM vs IFRX Comparison

Compare LITM & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LITM

Snow Lake Resources Ltd.

HOLD

Current Price

$3.83

Market Cap

63.6M

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$0.92

Market Cap

67.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LITM
IFRX
Founded
2018
2007
Country
Canada
Germany
Employees
N/A
N/A
Industry
Other Metals and Minerals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
63.6M
67.0M
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
LITM
IFRX
Price
$3.83
$0.92
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$8.50
AVG Volume (30 Days)
433.5K
677.7K
Earning Date
10-31-2025
03-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$73,729.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,054.36
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.34
$0.71
52 Week High
$13.78
$2.77

Technical Indicators

Market Signals
Indicator
LITM
IFRX
Relative Strength Index (RSI) 55.79 39.18
Support Level $3.10 $0.93
Resistance Level $3.70 $1.07
Average True Range (ATR) 0.34 0.08
MACD -0.01 -0.01
Stochastic Oscillator 73.26 9.88

Price Performance

Historical Comparison
LITM
IFRX

About LITM Snow Lake Resources Ltd.

Snow Lake Resources Ltd is a Canadian nuclear fuel cycle and critical minerals company with a portfolio of U.S.-focused uranium projects, including the Pine Ridge Uranium Project in the Powder River Basin in Wyoming. The company also holds exploration-stage critical minerals projects including the Snow Lake Lithium Project, Shatford Lake Lithium Project, and Engo Valley Uranium Project in Manitoba, Canada, and Namibia. Snow Lake has investments in companies with critical minerals assets, including rare earths and lithium in North America. The primary commercial use for U3O8 is as fuel for nuclear power plants to generate electricity.

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: